LLY

994.12

+0.59%↑

JNJ

242.44

+0.88%↑

ABBV

225.42

-1.97%↓

NVS

160.81

+0.66%↑

AZN

192.56

-0.93%↓

LLY

994.12

+0.59%↑

JNJ

242.44

+0.88%↑

ABBV

225.42

-1.97%↓

NVS

160.81

+0.66%↑

AZN

192.56

-0.93%↓

LLY

994.12

+0.59%↑

JNJ

242.44

+0.88%↑

ABBV

225.42

-1.97%↓

NVS

160.81

+0.66%↑

AZN

192.56

-0.93%↓

LLY

994.12

+0.59%↑

JNJ

242.44

+0.88%↑

ABBV

225.42

-1.97%↓

NVS

160.81

+0.66%↑

AZN

192.56

-0.93%↓

LLY

994.12

+0.59%↑

JNJ

242.44

+0.88%↑

ABBV

225.42

-1.97%↓

NVS

160.81

+0.66%↑

AZN

192.56

-0.93%↓

Search

Crinetics Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

38.12 -0.42

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

37.81

Massimo

38.92

Metriche Chiave

By Trading Economics

Entrata

7.3M

-123M

Vendite

3.7M

3.9M

EPS

-1.29

Margine di Profitto

-3,161.261

Dipendenti

437

EBITDA

20M

-122M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+130.19% upside

Dividendi

By Dow Jones

Utili prossimi

7 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-319M

4.2B

Apertura precedente

38.54

Chiusura precedente

38.12

Notizie sul Sentiment di mercato

By Acuity

40%

60%

86 / 351 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 mar 2026, 19:32 UTC

Acquisizioni, Fusioni, Takeovers

Diana Shipping Increases Offer to Acquire Genco -- Update

8 mar 2026, 23:47 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Equities Roundup: Market Talk

8 mar 2026, 23:47 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Nikkei May Fall on Higher Energy Prices, Signs of U.S. Econ Weakness -- Market Talk

8 mar 2026, 23:46 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Falls Amid Dollar's Strength -- Market Talk

8 mar 2026, 23:34 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Futures Surge Above $100/bbl Amid Growing Middle East Conflict -- Market Talk

8 mar 2026, 23:08 UTC

Principali Notizie su Eventi

Front-month WTI Crude Futures Jump 16.6%, Front-Month Brent Crude Futures Climb 15.2%

8 mar 2026, 23:05 UTC

Principali Notizie su Eventi

Front-month Crude Oil Futures Surge Amid Rising Middle East Conflict

8 mar 2026, 22:37 UTC

Principali Notizie su Eventi

The Long-Feared Persian Gulf Oil Squeeze Is Upon -2-

8 mar 2026, 22:37 UTC

Principali Notizie su Eventi

The Long-Feared Persian Gulf Oil Squeeze Is Upon Us -- WSJ

7 mar 2026, 02:30 UTC

Principali Notizie su Eventi

Iran War Is Kicking India When It's Already Down -- Barrons.com

6 mar 2026, 22:26 UTC

Principali Notizie su Eventi

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mar 2026, 22:07 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mar 2026, 22:03 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

6 mar 2026, 22:03 UTC

Discorsi di Mercato

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mar 2026, 21:50 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Financial Services Roundup: Market Talk

6 mar 2026, 21:37 UTC

Utili

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mar 2026, 21:25 UTC

Principali Notizie su Eventi

How The Iran War Impacts Ukraine. -- Barrons.com

6 mar 2026, 21:17 UTC

Utili

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mar 2026, 20:50 UTC

Utili

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mar 2026, 20:46 UTC

Utili

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mar 2026, 20:31 UTC

Principali Notizie su Eventi

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mar 2026, 20:18 UTC

Discorsi di Mercato

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mar 2026, 20:12 UTC

Discorsi di Mercato
Principali Notizie su Eventi

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mar 2026, 19:10 UTC

Discorsi di Mercato
Principali Notizie su Eventi

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mar 2026, 18:54 UTC

Discorsi di Mercato

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mar 2026, 18:44 UTC

Discorsi di Mercato
Principali Notizie su Eventi

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mar 2026, 18:08 UTC

Utili

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 18:04 UTC

Utili

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 18:04 UTC

Utili

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 17:49 UTC

Discorsi di Mercato

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

130.19% in crescita

Previsioni per 12 mesi

Media 88 USD  130.19%

Alto 97 USD

Basso 67 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

12

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

86 / 351 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat